Interview with Judith Greciet, President, Eisai France
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
Address: Laboratoires Eisai, Tour Manhattan 5/6 Place de l’Iris 92095 Paris La Defense cedex 2,France
Tel: +33-1-47 67 00 05
Web: http://www.eisai.fr/
Established in 1941 Eisai Inc. is the 26th ranked pharmaceutical lab in the world and 4th largest Japanese with a turnover of $5,6 billion a year worldwide. It began internationalizing in the 1980s and entered the French market in 1996 where it is currently ranked within the top 30 laboratories in France with over €161 million in sales.
Central Nervous System
Gastrointestinal Disorders
Cancer
Acute Care
Cardiovascular
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as…
Mathilde Lignot-Leloup, director of the French Social Security, provides a fascinating look into the French social system and speaks about its ongoing transformation. She elaborates on change management processes within…
Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also…
Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access…
Guy Maugis, president of the Franco-German Chamber of Commerce and Industry, explains the impact of the Macron government on the attractiveness of France as well as the importance of a…
Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to…
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
In this exclusive interview, David Loew, executive vice president of Sanofi Pasteur, discusses the future of vaccines in France and the rest of the world, their strategic role in reducing…
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core…
Jean-Luc Belingard, president of FEFIS (Fédération Française des Industries de Santé – French Federation of the Health Industry), explains his role following up on the implementation of the CSIS (Conseil…
Jean-Yves Berthon, CEO of French plant biotechnology pioneers GREENTECH discusses the key milestones in the company’s development trajectory, diversification plans and potential M&A activity. Our speciality is the extraction,…
See our Cookie Privacy Policy Here